PL2054406T3 - Nukleozydy do hamowania lub zmniejszania powstawania oporności w przypadku leczenia cytostatykami - Google Patents
Nukleozydy do hamowania lub zmniejszania powstawania oporności w przypadku leczenia cytostatykamiInfo
- Publication number
- PL2054406T3 PL2054406T3 PL07786668T PL07786668T PL2054406T3 PL 2054406 T3 PL2054406 T3 PL 2054406T3 PL 07786668 T PL07786668 T PL 07786668T PL 07786668 T PL07786668 T PL 07786668T PL 2054406 T3 PL2054406 T3 PL 2054406T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleosides
- suppressing
- development
- resistance
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006037786A DE102006037786A1 (de) | 2006-08-11 | 2006-08-11 | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
PCT/EP2007/007147 WO2008017515A1 (de) | 2006-08-11 | 2007-08-13 | Nukleoside zur unterdrückung oder reduzierung der resistenzbildung bei der zytostatika-behandlung |
EP07786668.9A EP2054406B1 (de) | 2006-08-11 | 2007-08-13 | Nukleoside zur unterdrückung oder reduzierung der resistenzbildung bei der zytostatika-behandlung |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2054406T3 true PL2054406T3 (pl) | 2016-04-29 |
Family
ID=38537796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07786668T PL2054406T3 (pl) | 2006-08-11 | 2007-08-13 | Nukleozydy do hamowania lub zmniejszania powstawania oporności w przypadku leczenia cytostatykami |
Country Status (16)
Country | Link |
---|---|
US (1) | US8492537B2 (pl) |
EP (1) | EP2054406B1 (pl) |
JP (1) | JP5461989B2 (pl) |
KR (1) | KR101113029B1 (pl) |
CN (1) | CN101522666B (pl) |
AU (1) | AU2007283729B2 (pl) |
BR (1) | BRPI0716425A2 (pl) |
CA (1) | CA2660636C (pl) |
DE (1) | DE102006037786A1 (pl) |
DK (1) | DK2054406T3 (pl) |
ES (1) | ES2553404T3 (pl) |
HU (1) | HUE028077T2 (pl) |
MX (1) | MX2009001433A (pl) |
PL (1) | PL2054406T3 (pl) |
PT (1) | PT2054406E (pl) |
WO (1) | WO2008017515A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2785395A1 (en) * | 2009-12-23 | 2011-06-30 | Board Of Regents Of The University Of Nebraska | Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer |
HUE041509T2 (hu) | 2011-12-22 | 2019-05-28 | Janssen Biopharma Inc | Szubsztituált nukleozidok, nukleotidok és ezek analógjai |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EP3074411A2 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of liver cancer |
CN107540718B (zh) * | 2017-10-26 | 2020-01-31 | 天津立博美华基因科技有限责任公司 | 1-(2-脱氧-β-D-呋喃核糖基)-5-碘-2-嘧啶酮的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8100177A (nl) * | 1981-01-15 | 1982-08-02 | Stichting Rega V Z W | 3'-amino- of -azidoderivaten van e-5-(2-halogeenvinyl)-2'-deoxyuridine. |
HU183567B (en) | 1981-09-07 | 1984-05-28 | Mta Koezponti Kemiai Kutato In | Process for preparing /e/-5-/2-bromo-vinyl/-uridine and derivatives thereof |
EP0097039A1 (en) | 1982-06-16 | 1983-12-28 | Beecham Group Plc | 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections |
EP0104857A1 (en) | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
DD251984A5 (de) * | 1985-09-17 | 1987-12-02 | The Wellcome Foundation Limited,Gb | Verfahren zur herstellung von 3'-azidonucleosiden und pharmazeutisch vertraeglichen derivaten davon |
US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
GB8912972D0 (en) | 1989-06-06 | 1989-07-26 | Wellcome Found | Therapeutic nucleosides |
DD288827A5 (de) * | 1989-11-07 | 1991-04-11 | Adw Zi F. Molekularbiologie,De | Verfahren zur herstellung von 5-vinyl-analoga des 2',3'-diedesoxy-3'-fluoruridins |
DE19545892A1 (de) * | 1995-12-08 | 1997-06-12 | Fraunhofer Ges Forschung | Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU |
DK0806956T3 (da) | 1995-02-01 | 2003-01-06 | Resprotect Gmbh | Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling |
JP2001518931A (ja) | 1997-03-24 | 2001-10-16 | イーライ・リリー・アンド・カンパニー | ジフルオロヌクレオシドホスホン酸とその誘導体 |
ES2172303T3 (es) * | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
PT1411954E (pt) * | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
US20020147175A1 (en) | 2000-11-16 | 2002-10-10 | Shepard H. Michael | Synergistic ECTA compositions |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
DE10313035A1 (de) * | 2003-03-24 | 2004-10-07 | Resprotect Gmbh | Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
EP1674104A1 (en) * | 2004-12-24 | 2006-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV |
-
2006
- 2006-08-11 DE DE102006037786A patent/DE102006037786A1/de not_active Ceased
-
2007
- 2007-08-13 PT PT77866689T patent/PT2054406E/pt unknown
- 2007-08-13 MX MX2009001433A patent/MX2009001433A/es active IP Right Grant
- 2007-08-13 CA CA2660636A patent/CA2660636C/en not_active Expired - Fee Related
- 2007-08-13 HU HUE07786668A patent/HUE028077T2/en unknown
- 2007-08-13 BR BRPI0716425-4A2A patent/BRPI0716425A2/pt not_active IP Right Cessation
- 2007-08-13 WO PCT/EP2007/007147 patent/WO2008017515A1/de active Application Filing
- 2007-08-13 DK DK07786668.9T patent/DK2054406T3/en active
- 2007-08-13 ES ES07786668.9T patent/ES2553404T3/es active Active
- 2007-08-13 PL PL07786668T patent/PL2054406T3/pl unknown
- 2007-08-13 US US12/377,239 patent/US8492537B2/en not_active Expired - Fee Related
- 2007-08-13 EP EP07786668.9A patent/EP2054406B1/de not_active Not-in-force
- 2007-08-13 JP JP2009523208A patent/JP5461989B2/ja not_active Expired - Fee Related
- 2007-08-13 AU AU2007283729A patent/AU2007283729B2/en not_active Ceased
- 2007-08-13 CN CN200780036649.7A patent/CN101522666B/zh not_active Expired - Fee Related
- 2007-08-13 KR KR1020097004398A patent/KR101113029B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK2054406T3 (en) | 2015-11-30 |
ES2553404T3 (es) | 2015-12-09 |
MX2009001433A (es) | 2009-04-09 |
CA2660636C (en) | 2015-10-06 |
KR20090040905A (ko) | 2009-04-27 |
JP5461989B2 (ja) | 2014-04-02 |
HUE028077T2 (en) | 2016-11-28 |
DE102006037786A1 (de) | 2008-03-20 |
US20100227834A1 (en) | 2010-09-09 |
AU2007283729A1 (en) | 2008-02-14 |
EP2054406B1 (de) | 2015-10-07 |
CN101522666A (zh) | 2009-09-02 |
BRPI0716425A2 (pt) | 2013-12-03 |
US8492537B2 (en) | 2013-07-23 |
CA2660636A1 (en) | 2008-02-14 |
CN101522666B (zh) | 2014-01-22 |
PT2054406E (pt) | 2015-11-30 |
JP2010500307A (ja) | 2010-01-07 |
WO2008017515A1 (de) | 2008-02-14 |
KR101113029B1 (ko) | 2012-06-05 |
AU2007283729B2 (en) | 2011-09-01 |
EP2054406A1 (de) | 2009-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2032168A4 (en) | COMBINED THERAPY BASED ON CAPECITABINE | |
IL196559A0 (en) | Combination therapy | |
IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
GB0625659D0 (en) | Therapeutic compounds and their use | |
EP2062596A4 (en) | ANTI-TUMOR AGENT | |
IL196702A0 (en) | Trauma therapy | |
HUE037109T2 (hu) | Endoxifén rák kezelésében történõ alkalmazásra | |
IL196556A0 (en) | Combination therapy | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
EP2054061A4 (en) | COMBINATION THERAPY | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
PT2054406E (pt) | Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática | |
PL2012805T3 (pl) | Kompozycja lecznicza i jej zastosowanie | |
PL2061458T3 (pl) | Kompozycje topiramatu i sposoby ich stosowania | |
HK1183623A1 (en) | Antiviral method and composition | |
GB0607946D0 (en) | Mono and combination therapy | |
IL198026A0 (en) | Sequential combination therapy | |
ZA200902203B (en) | Combination therapy | |
GB2441007B (en) | Auricular therapy | |
GB0606660D0 (en) | Targeted Therapy | |
ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
GB0614538D0 (en) | Therapeutic Compounds And Their Use | |
GB2437719B (en) | Body panel insert | |
GB0601818D0 (en) | Therapeutic agent | |
GB0620514D0 (en) | Therapeutic composition |